The platform includes multiple TCR generation and optimization technologies (e.g., Allogeneic-HLA (Allo-HLA) TCR Priming), as well as product enhancement technologies (e.g., PD1-41BB and CD40L-CD28 Costimulatory Switch Proteins, Precision Pairing) to address challenges in developing effective, durable and safe TCR-T therapies. Partnerships with multiple companies including BioNTech and 2seventy bio, continue to validate the platform's assets and technologies. For more information, please refer to the recent publication by Dolores J. Schendel, published in Frontiers in Oncology, section Molecular and Cellular Oncology: Evolution by Innovation as a Driving Force to Improve TCR-T Therapies.